The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The importance of raising awareness about genomic testing in CLL & existing and emerging biomarkers
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, discusses the importance of raising awareness about genomic testing in patients with chronic lymphocytic leukemia (CLL) prior to treatment initiation. Prof. Ghia further describes the emergence of novel biomarkers in CLL which are currently under investigation. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
